Sera Prognostics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sera Prognostics, Inc.
Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.
Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bi-monthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. This month we highlight deals announced in January and February 2017.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.